PHARMAENGINE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 93.3 TWD | 0.00% |
|
-0.53% | -11.56% |
| 05-02 | PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-24 | PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors | CI |
ETFs positioned on PharmaEngine, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 0 M€ | +3.95% | - | |
| 0.00% | 0 M€ | +3.63% | - |
PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
93.3
TWD
Average target price
106
TWD
Spread / Average Target
+13.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.56% | 413M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- 4162 Stock
- Funds and ETFs PharmaEngine, Inc.
